The effect of consuming olive oil in patients with depression

The effect of consuming olive oil on depression, lipid profile, salivary cortisol and brain derived neurotrophic factor in patients with depression

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016041720140N2

Enrollment

Registered

2016-06-03

Start date

2015-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Depressive episode

Interventions

Intervention 1: The intervention group: Daily consumption of 25 milliliters extra virgin olive oil for duration of 52 days. Intervention 2: The control group: Daily consumption of 25 milliliters sunfl

Lifestyle

Placebo

The intervention group: Daily consumption of 25 milliliters extra virgin olive oil for duration of 52 days

The control group: Daily consumption of 25 milliliters sunflower oil for duration of 52 days

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Suffering from major depression based on criteria of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; aged 18 to 65 years old; routine consumption of sunflower oil; without allergy to olive or sunflower or their products; without fat malabsorption; a score of less than or equal to 7 in 14 item questionnaire of Mediterranean diet adherence and ability and willingness to participate in the study. Exclusion criteria: Use of lipid lowering medications; use of corticosteroid medications; suffering from a concurrent serious mental disorder such as schizophrenia; suffering from severe or unstable medical conditions; alcohol or drug dependence; pregnancy; lactation; serious risk of homicide or suicide; the need for hospitalization; change in medications or treatments used for depression; change in diet or physical activity; consumption of less than 70% of the recommended oil and loss of any of the inclusion criteria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: The beginning, middle and end of the study. Method of measurement: Using two questionnaires of Beck Depression Inventory II and Hamilton Depression Rating Scale, 7 item version.;Serum lipid profile (triglycerides, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol). Timepoint: The beginning and end of the study. Method of measurement: In milligrams per deciliter using laboratory kits.;Salivary cortisol. Timepoint: The beginning and end of the study. Method of measurement: In nanogram per milliliter using the assay kit.;Serum brain derived neurotrophic factor. Timepoint: The beginning and end of the study. Method of measurement: In nanogram per milliliter using the assay kit.	—

Measure

Time frame

Depression. Timepoint: The beginning, middle and end of the study. Method of measurement: Using two questionnaires of Beck Depression Inventory II and Hamilton Depression Rating Scale, 7 item version.;Serum lipid profile (triglycerides, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol). Timepoint: The beginning and end of the study. Method of measurement: In milligrams per deciliter using laboratory kits.;Salivary cortisol. Timepoint: The beginning and end of the study. Method of measurement: In nanogram per milliliter using the assay kit.;Serum brain derived neurotrophic factor. Timepoint: The beginning and end of the study. Method of measurement: In nanogram per milliliter using the assay kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Foshati

Shiraz University of Medical Sciences

foshatis@sums.ac.ir; s.foshati@gmail.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026